1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  
March 2018  
April 2018  
May 2018  
June 2018  
July 2018  

This page is powered by Blogger. Isn't yours?

Tuesday, July 19, 2016

 

Alzheimer's vaccine steps closer with new study





























A vaccine for Alzheimer's disease could be trialed in humans within the next 3-5 years, after researchers from the United States and Australia have uncovered a formulation that they say successfully targets brain proteins that play a role in development and progression of the disease.

Study co-author Prof. Nikolai Petrovsky, of Flinders University School of Medicine in Australia, and colleagues reveal how a vaccine combination generates antibodies that target beta-amyloid and tau proteins in the brain - both of which are considered hallmarks of Alzheimer's disease.

Beta-amyloid is known to accumulate in the brains of people with Alzheimer's, forming plaques, while the tau protein forms tangles. Plaques and tangles are believed to disrupt signaling between nerve cells and contribute to nerve cell death.

"[The proteins are] a bit like the car in your driveway," Prof. Petrovsky explained to ABC Adelaide. "You need to remove them from the brain otherwise if you left broken down cars in your driveway eventually you couldn't get out."

"Essentially that's what happens in people who get Alzheimer's or dementia is they have lots of these broken down proteins in the brain."

Reporting in the journal Scientific Reports, the team describes how the vaccine formulation has proven safe and effective in mouse models of Alzheimer's, and it has also successfully targeted beta-amyloid and tau proteins in human brain tissue.

Vaccine combo boosts antibody response to Alzheimer's proteins
Researchers have spent decades searching for ways to prevent and treat Alzheimer's, but success has been limited.

Between 2002-2012, 413 clinical trials were conducted worldwide that assessed the safety and efficacy of 244 compounds against Alzheimer's. Only one new drug came out of these trials - representing a 0.4 percent success rate - and this drug only induces short-term relief of Alzheimer's symptoms.

As a result of such poor outcomes from clinical trials to date, the National Institutes of Health (NIH) increased their funding for Alzheimer's research by $350 million, bringing the total funding for research in the U.S. to $1.3 billion this year.

According to Prof. Petrovsky and colleagues, such funding has led to the development of their "exceptional" vaccine, which they say is comprised of a MultiTEP vaccine platform and Advax.

The team explains that the MultiTEP approach produces high antibody responses to beta-amyloid and tau proteins either independently or combined, while Advax is an adjuvant vaccine that further boosts the antibody response.

In their study, the researchers found that the formulation was effective and well-tolerated in Alzheimer's mouse models, with no reports of adverse reactions. The vaccine was also able to target the proteins in brain tissue from patients with Alzheimer's.

"This study suggests that we can immunize patients at the early stages of AD [Alzheimer's disease], or even healthy people at risk for AD, using our anti-amyloid-beta vaccine, and, if the disease progresses, then vaccinate with another anti-tau vaccine to increase effectiveness."

Study co-author Prof. Michael Agadjanyan, Institute for Molecular Medicine, California

According to the Alzheimer's Association, around 5.4 million people in the U.S. are living with Alzheimer's, and this number is expected to almost triple by 2050 unless new, effective treatment strategies are uncovered.

The researchers say they will be working with four companies to assess the non-clinical safety and toxicology of the vaccine, which is required under the U.S. Food and Drug Administration's (FDA) Investigational New Drug program.

If the vaccine continues to show success in these preclinical trials, the researchers say they could be testing the vaccine in individuals at high risk for Alzheimer's or those in the early stages of the disease within the next 3-5 years.

Story Source: The above story is based on materials provided by MEDICALNEWSTODAY
Note: Materials may be edited for content and length